Metabolon Logo
Metabolon Logo

Metabolon Receives NIH Grant to Develop Advanced Monitoring and Predictive Tools for Type 1 Diabetes Progression

Posted In: Company News

MORRISVILLE, N.C. – June 25, 2024 – Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, is proud to announce the receipt of a prestigious grant from the National Institutes of Health (NIH) to develop an innovative product aimed at better monitoring and predicting the conversion of preclinical asymptomatic type 1 diabetes (T1D) to clinical symptomatic, insulin-dependent type 1 diabetes.

Over 3 million people in the United States live with T1D.  Today, the biomarkers that predict the progression of preclinical T1D to clinical T1D lack specificity and granularity.  Despite advances in medical research, no single FDA-approved test currently can monitor T1D progression beyond simple disease staging.  Metabolon’s new initiative addresses this unmet need by identifying metabolite biomarkers to improve prediction and enable a more detailed understanding of disease progression when evaluated alongside current clinical indicators.

“Metabolon has a rich history of pioneering advancements in metabolomics.  We are dedicated to empowering pharmaceutical and biotechnology companies, as well as academic and government institutions, with comprehensive metabolic insights to drive better health outcomes,” said Ro Hastie, CEO of Metabolon.  “With this NIH grant, Metabolon is poised to extend its expertise in T1D, aiming to enhance predictive capabilities and improve the lives of millions affected by this condition.”

If successful, Metabolon’s research will enhance the specificity and granularity of T1D progression prediction and pave the way for more precise and personalized treatment strategies.  By integrating new metabolite biomarkers with existing clinical indicators, Metabolon’s efforts will significantly contribute to diabetes research and patient care.  For more information about Metabolon’s projects and services, please visit

Contact Us

Talk with an expert

Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.

Corporate Headquarters

617 Davis Drive, Suite 100
Morrisville, NC 27560

+1 (919) 572-1721